NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

神經退化性疾病:現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析

Neurodegenerative Diseases - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版商 GervanoRA Data Services LLP 商品編碼 1024233
出版日期 內容資訊 英文 333 Pages
商品交期: 3-5個工作天內
價格
神經退化性疾病:現在的市場機會和今後的預測,流行病學研究,市場動態,開發平台分析,風險調整淨現值(r-NPV)分析 Neurodegenerative Diseases - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
出版日期: 2021年08月11日內容資訊: 英文 333 Pages
簡介

本報告提供神經退化性疾病市場調查,彙整市場及疾病概要,市場趨勢,流行病學調查,進行中的研究開發概要,新加入企業的市場佔有率預測及價格策略,風險調整淨現值(r-NPV)分析,開發階段·給藥途徑·作用機制·藥物類別·分子類型·標的·企業類型·各地區的開發平台(管線)的概述及比較分析,未滿足需求,開發平台藥物的專利趨勢,到2030年前的市場預測,治療領域的交易趨勢等資料。

目錄

第1章 簡介

第2章 摘要整理

第3章 疾病概要與流行病學研究

第4章 神經退化性疾病的市場規模的變化與預測(2020年∼2030年)

第5章 開發平台(管線)的洞察和基準預測

第6章 神經退化性疾病的交易趨勢

第7章 神經退化性疾病的開發平台藥物的專利比較分析

第8章 風險調整淨現值(r-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH632

GervanoRA's pipeline analysis and opportunity assessment report "Neurodegenerative Diseases - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Neurodegenerative Diseases pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Neurodegenerative Diseases drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Neurodegenerative Diseases area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Neurodegenerative Diseases drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Neurodegenerative Diseases historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Neurodegenerative Diseases Market (2020) and the Forecasted Neurodegenerative Diseases Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Neurodegenerative Diseases Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Neurodegenerative Diseases Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Neurodegenerative Diseases Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: NEURODEGENERATIVE DISEASES CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF NEURODEGENERATIVE DISEASES COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF NEURODEGENERATIVE DISEASES PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: ALZHEIMER'S DISEASE EPIDEMIOLOGY (2020) AND FORECAST (2021-2030) IN MILLION
  • TABLE 03: PARKINSON'S DISEASE EPIDEMIOLOGY (2020) AND FORECAST (2021-2030) IN MILLION
  • TABLE 04: NEURODEGENERATIVE DISEASES MAJOR COLLABORATION DEALS, BY DEAL AMOUNT
  • TABLE 05: NEURODEGENERATIVE DISEASES MAJOR MERGER AND ACQUISITION DEALS
  • TABLE 06: NEURODEGENERATIVE DISEASES MAJOR FINANCING DEALS, BY DEAL AMOUNT
  • TABLE 07: NEURODEGENERATIVE DISEASES MAJOR LICENSING DEALS, BY DEAL AMOUNT
  • TABLE 08: MAJOR DEALS FOR NEURODEGENERATIVE DISEASES (2020)
  • TABLE 09: OVERVIEW OF COMPANY PATENT EXPIRIES
  • TABLE 10: NEURODEGENERATIVE PIPELINE MOLECULES BY STAGE OF DEVELOPMENT AND TOP 5 INDICATIONS
  • TABLE 11: PHASE 3 MOLECULES IN ALZHEIMER'S DISEASE DRUG PIPELINE
  • TABLE 12: PHASE 2 MOLECULES IN ALZHEIMER'S DISEASE DRUG PIPELINE
  • TABLE 13: PHASE 1 MOLECULES IN ALZHEIMER'S DISEASE DRUG PIPELINE
  • TABLE 14: PRECLINICAL MOLECULES IN ALZHEIMER'S DISEASE DRUG PIPELINE
  • TABLE 15: R&D MOLECULES IN ALZHEIMER'S DISEASE DRUG PIPELINE
  • TABLE 16: PIPELINE ANALYTICS BY DRUG CLASS, ALZHEIMER'S DISEASE
  • TABLE 17: PIPELINE ANALYTICS BY MECHANISM OF ACTION, ALZHEIMER'S DISEASE
  • TABLE 18: PRE-REGISTRATION MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 19: PHASE 3 MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 20: PHASE 2 MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 21: PHASE 1 MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 22: PRECLINICAL MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 23: R&D MOLECULES IN PARKINSON'S DISEASE DRUG PIPELINE
  • TABLE 24: PIPELINE ANALYTICS BY DRUG CLASS, PARKINSON'S DISEASE
  • TABLE 25: PIPELINE ANALYTICS BY MECHANISM OF ACTION, PARKINSON'S DISEASE
  • TABLE 26: PHASE 3 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 27: PHASE 2 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 28: PHASE 1 MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 29: PRECLINICAL MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 30: EARLY R&D MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE
  • TABLE 31: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE ANALYSIS BY ORAL ROA
  • TABLE 32: AMYOTROPHIC LATERAL SCLEROSIS PIPELINE MOLECULES BY INJECTABLE AS ROA
  • TABLE 33: CELL THERAPIES AND GENE THERAPIES UNDER DEVELOPMENT FOR ALS
  • TABLE 34: RECENTLY APPROVED DRUGS FOR MULTIPLE SCLEROSIS
  • TABLE 35: PHASE 3 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 36: PHASE 2 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 37: PHASE 1 MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 38: PRECLINICAL MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 39: EARLY R&D MOLECULES IN MULTIPLE SCLEROSIS DRUG PIPELINE
  • TABLE 40: ORALLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 41: INTRAVENOUSLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 42: SUBCUTANEOUSLY ADMINISTERED KEY PIPELINE MOLECULES
  • TABLE 43: PHASE 2 MOLECULES IN HUNTINGTON'S DISEASE DRUG PIPELINE
  • TABLE 44: PHASE 1 MOLECULES IN HUNTINGTON'S DISEASE DRUG PIPELINE
  • TABLE 45: PRECLINICAL MOLECULES IN HUNTINGTON'S DISEASE DRUG PIPELINE
  • TABLE 46: EARLY R&D MOLECULES IN HUNTINGTON'S DISEASE DRUG PIPELINE
  • TABLE 47: HUNTINGTON'S DISEASE PIPELINE MOLECULES BY ORAL ROA
  • TABLE 48: HUNTINGTON'S DISEASE PIPELINE MOLECULES BY INJECTABLE ROA
  • TABLE 49: DRUG CLASSES OF HUNTINGTON'S DISEASE PIPELINE DRUG CANDIDATES
  • TABLE 50: PROGRESSIVE SUPRANUCLEAR PALSY DRUG MOLECULES IN PIPELINE

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: NEURODEGENERATIVE DISEASES COVERED IN THE REPORT
  • FIGURE 02: ALZHEIMER'S DISEASE EPIDEMIOLOGY FORECAST (US)
  • FIGURE 03: EPIDEMIOLOGY FORECAST PARKINSON'S DISEASE (GLOBAL)
  • FIGURE 04: ALS EPIDEMIOLOGY FORECAST (2021-2030), US
  • FIGURE 05: ALS EPIDEMIOLOGY FORECAST (2021-2030), EUROPE
  • FIGURE 06: NEURODEGENERATIVE DISEASES DEALS BY DEAL TYPE
  • FIGURE 07: NEURODEGENERATIVE DISEASES DEALS FREQUENCY IN 2019
  • FIGURE 08: NEURODEGENERATIVE DISEASE DEALS FREQUENCY IN 2018
  • FIGURE 09: NEURODEGENERATIVE DISEASES DEALS FREQUENCY IN 2017
  • FIGURE 10: NEURODEGENERATIVE DISEASES DEALS FREQUENCY IN 2016
  • FIGURE 11: NEURODEGENERATIVE DISEASES DEALS FREQUENCY IN 2015
  • FIGURE 12: ALZHEIMER'S DISEASE DEALS, BY DEAL TYPE
  • FIGURE 13: PARKINSON'S DISEASE DEALS, BY DEAL TYPE
  • FIGURE 14: AMYOTROPHIC LATERAL SCLEROSIS DEALS, BY DEAL TYPE

FUGURE 15: MULTIPLE SCLEROSIS DEALS, BY DEAL TYPE

  • FIGURE 16: HUNTINGTON'S DISEASE DEALS, BY DEAL TYPE
  • FIGURE 17: ALZHEIMER'S DISEASE PIPELINE DRUGS WITH RESPECT TO STAGE OF DEVELOPMENT
  • FIGURE 18: PIPELINE ANALYTICS BY GEOGRAPHY
  • FIGURE 19: PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
  • FIGURE 20: PARKINSON'S DISEASE PIPELINE DRUGS WITH RESPECT TO STAGE OF DEVELOPMENT
  • FIGURE 21: PIPELINE ANALYTICS BY GEOGRAPHY
  • FIGURE 22: PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION
  • FIGURE 23: PIPELINE MOLECULES IN AMYOTROPHIC LATERAL SCLEROSIS AREA, PERCENT SHARE
  • FIGURE 24: ALS PIPELINE SPLIT BY GEOGRAPHY, NUMBER OF EXPECTED DRUG APPROVALS
  • FIGURE 25: AMYOTROPHIC LATERAL SCLEROSIS DRUG PIPELINE SPLIT BY GEOGRAPHY